Navigation Links
SCOLR Pharma, Inc. Reports Third Quarter 2010 Financial Results
Date:11/10/2010

//www.scolr.com/.

This press release contains forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning anticipated sales of our nutritional products and the timing thereof, the timing of anticipated shipment of our nutritional products, our expectations concerning conduct of the actual use study for our ibuprofen product, our expectations concerning regulatory approval of our pseudoephedrine product and the anticipated timing of such approval. These forward-looking statements involve risks and uncertainties, including activities, events or developments that we expect, believe or anticipate will or may occur in the future. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including lower than expected demand by national retailers for our nutritional products, our ability to conform to the sales planning cycles of the retailers targeted as potential customers for our nutritional products, constraints on our liquidity related to the greater working capital requirements of our nutritional business, unanticipated changes in the timing or amount of orders for our nutritional products, unanticipated problems or delays with our regulatory applications, unanticipated costs and expenses associated with our product development, clinical activities and regulatory review,  reductions in our royalty revenues, our ability to create and maintain partnerships or other relationships, the continuation of arrangements with our product development partners, customers and clinical project services providers, competition, government regulation and general economic conditions. For example, if we are not able to meet the timing and other expectations of the retailers we have targeted as potential customers of our nutritional products, we may not be able to generate revenue from sales of these
'/>"/>

SOURCE SCOLR Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. SCOLR Pharma, Inc. Names Carl Johnson as Chairman; Former Chairman Michael Taglich Remains as Director
2. SCOLR Pharma, Inc. Signs Agreement with The Emerson Group to Provide Sales Support for Nutritional & OTC Products
3. SCOLR Pharma, Inc. Enters into Worldwide Licensing Agreement with RedHill Biopharma Ltd.
4. SCOLR Pharma, Inc. Licenses Dietary Supplements
5. SCOLR Pharma, Inc. Receives Notices From NYSE Amex LLC Regarding Compliance Plan and Listing Standards
6. SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results
7. SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results
8. SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen
9. Reportlinker Adds Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics, 4th edition
10. Reportlinker Adds Co-promotion and Co-marketing Agreements in Pharma, Biotech and Diagnostics, 4th Edition
11. Horizon Pharma, Inc. Files Registration Statement for Proposed Initial Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 27, 2015 Levi & Korsinsky announces it ... OHRP ) concerning possible violations of federal securities ... Company in connection with its study of the drug ... or contact Joseph E. Levi, Esq. ... telephone at (212) 363-7500, toll-free: (877) 363-5972. ...
(Date:3/27/2015)... MONTREAL , March 27, 2015 /CNW Telbec/ - ... Research-Based Pharmaceutical Companies (Rx&D), welcomes the 2015-2016 ... of a working group on the biopharmaceutical industry. However, ... medicines budget. "We commend the government,s intent ... the announcement of measures to promote Quebec,s ...
(Date:3/27/2015)... The Temple Health & Bioscience District (THBD) today announced it ... South First St. in the Temple Medical and Education District ... of Temple to receive funding for redevelopment. Located ... Health Care System, the new facility will enable THBD to ... life science companies. Temple ...
Breaking Medicine Technology:Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 2Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 3Temple Health & Bioscience District Relocates, Offers Office And Lab Space To Biotech Companies 2
... 2011 Samplify Systems, Inc., a leading provider of ... scientific markets, has completed its Series B round of ... fund its rapid growth in its existing markets, and ... the round are Integrated Device Technology, Inc. (Nasdaq: ...
... THOUSAND OAKS, Calif., March 4, 2011 Amgen (Nasdaq: ... the acquisition of BioVex Group, Inc., a privately held ... in Abingdon, UK. The acquisition includes OncoVEX(GM-CSF), a novel ... may represent a new approach to treating melanoma and ...
Cached Medicine Technology:Samplify Systems Completes Series B Funding 2Samplify Systems Completes Series B Funding 3Amgen Completes Acquisition of BioVex 2Amgen Completes Acquisition of BioVex 3Amgen Completes Acquisition of BioVex 4
(Date:3/28/2015)... 28, 2015 Andrew Hawley of Vintage Rock ... psychedelic concert posters. The Who and the Doors played together ... 2, 1968. According to Hawley, “The Who toured the United ... and college campuses. Perhaps the most famous Who poster was ... and the Doors on August 2, 1968 at the Singer ...
(Date:3/28/2015)... Aureus Medical Group (web: aureusmedical.com), ... therapy jobs, has announced that it will participate ... Association Annual Conference to be held April 10-11, ... Columbus, OH. , The OPTA Annual Conference ... products and services. , Representatives from Aureus ...
(Date:3/28/2015)... 2015 The "Petrick Sustainable Health ... health. After 18 years of research and experience with ... contenders, Dr. Jon Petrick is excited to be launching ... of the immediate benefits of this radical new system ... of strength of the immune system, faster healing of ...
(Date:3/28/2015)... March 28, 2015 ARDX will sponsor the ... 12pm -3pm at the Chesapeake Conference Center in Chesapeake, Virginia. ... an empowering event for women in the Hampton Roads region. ... Stories of Women’s Lives. Women grow stronger through sharing ... other. This year the WWC™ theme is T-talk where ...
(Date:3/28/2015)... 28, 2015 Servpro of Paso ... week released a report about the link between mold ... sufferers, and according to recent medical research, may even ... to the Environmental Protection Agency, people with sensitivity to ... in mold may trigger asthma attacks for asthma sufferers. ...
Breaking Medicine News(10 mins):Health News:Avid Collector from Vintage Rock Posters, Inc. Announces His Search For Original 1960's Who Psychedelic Concert Posters. 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the Ohio Physical Therapy Association Annual Conference 2Health News:Celebrity Chiropractor Jon Petrick to Release Sustainable Health System this Summer 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 3
... peers are doing seems to matter, expert surmise, , MONDAY, ... friends really weren,t drinking as much as it might seem, ... , Researchers from Oxford Brookes University in England reviewed 22 ... States. The researchers divided the students into two groups: those ...
... NASHVILLE, Tenn., July 20 HealthLeaders-InterStudy, a leading ... the Los Angeles market are struggling to recruit physicians, particularly ... the recent Los Angeles Market Overview , ... to physicians, ranging from $250 to $4,000 a day, to ...
... , PITTSBURGH, July 20 Mylan Inc. (Nasdaq: ... million preferred stock issuance, the company has declared its quarterly dividend of ... a liquidation preference of $1,000.00 per share) payable on August 17, 2009, ... , , Mylan Inc., which provides products ...
... , SEATTLE, July 20 Group Health ... 15 quality measures in the Puget Sound Health Alliance Community ... any of the other nine medical groups in the Puget Sound region ... Health received no "below regional average" scores. , , ...
... , , CLEVELAND, July 20 ... global eClinical solutions for the clinical trials industry, announced today that ... DATATRAK CRO Connect Program(TM). ARA will utilize DATATRAK eClinical(TM) to ... paper and EDC clients. , , ...
... , , ... 20 Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX ) today announced that ... drug for the treatment of obesity, met their co-primary endpoints. The results ... besity R esearch, or COR, program of more than 4,500 ...
Cached Medicine News:Health News:Perception May Affect Drinking by College Students 2Health News:l.a. Hospitals Struggle for Emergency Room Care, Pay Physicians High Fees for On-Call Coverage 2Health News:Group Health Cooperative Scored Above Regional Average in 11 of 15 Quality Measures 2Health News:Advance Research Associates Joins DATATRAK's CRO Connect Program(TM) 2Health News:Advance Research Associates Joins DATATRAK's CRO Connect Program(TM) 3Health News:Advance Research Associates Joins DATATRAK's CRO Connect Program(TM) 4Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 2Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 3Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 4Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 5Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 6Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 7Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 8Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 9
... ,The S/5 Critical Care Monitor is a multiparameter ... varying needs of critical care. The S/5 Critical ... options, display and mounting options, remote control and ... set-up to help meet your needs. The new ...
... for size., ,The Datex-Ohmeda S/5 Light Monitor ... in anesthesia and critical care areas, in emergency ... transport. As part of the Datex-Ohmeda S/5 family, ... user interface and design shared by all S/5 ...
... to use., ,The S/5 Compact Critical ... ideally suited for medium care monitoring. The ... Datex-Ohmeda supplies and accessories., ,The S/5 ... user interface and features as the S/5 ...
... need in day surgery and post anesthesia care ... Anesthesia Monitor is a high performance monitor designed ... anesthesia care and induction rooms. It offers the ... parameters and advanced airway gas monitoring. When paired ...
Medicine Products: